Virios Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Members' Deficit

Members' Deficit	3 Months Ended
Mar. 31, 2021
Members' Deficit
Members' Deficit	7Members’ Deficit At March 31, 2020, the Company was authorized to issue two classes of membership interests, voting and non-voting. Dr. William Pridgen, the Founder, held the only voting membership interest of the Company. There was no value assigned to voting membership interest on the balance sheet as of March 31, 2020, as the Founder’s membership interest was granted for contributed patents that were not assigned a value under U.S. GAAP. In conjunction with the Corporate Conversion, all of the Company’s outstanding membership interests converted into shares of common stock.

Members' Deficit

3 Months Ended

Mar. 31, 2021

7Members’ Deficit

At March 31, 2020, the Company was authorized to issue two classes of membership interests, voting and non-voting. Dr. William Pridgen, the Founder, held the only voting membership interest of the Company. There was no value assigned to voting membership interest on the balance sheet as of March 31, 2020, as the Founder’s membership interest was granted for contributed patents that were not assigned a value under U.S. GAAP.

In conjunction with the Corporate Conversion, all of the Company’s outstanding membership interests converted into shares of common stock.